Vilicom Selects Mavenir to Deliver UK’s First Off-Shore Open RAN based vRAN Private Network for Windfarm Connectivity
26.8.2021 10:00:00 EEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announces today that UK based wireless telecommunications provider, Vilicom is using the MAVair solution as a critical component in delivering UK’s first off-shore private LTE network for windfarm communications and connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005014/en/
Moray East Offshore Windfarm, Scotland, United Kingdom. Vilicom Selects Mavenir to Deliver UK’s First Off-Shore Open RAN based vRAN Private Network for Windfarm Connectivity. (Photo: Business Wire)
The MAVair family includes the flexible Open Virtualised RAN (Open vRAN) where the evolved RAN architecture, designed with cloud-native virtualisation techniques, enables the RAN to flex and adapt based on usage and coverage. Mavenir’s Open vRAN platform enables Vilicom to provide reliable, scalable, high throughput solution meeting low latency requirement in a challenging environment. The software application runs on commoditised hardware providing cost effectiveness, high flexibility and agility to network operators, whilst providing one architecture for many different user scenarios.
The Vilicom network provides advanced communications and connectivity to sea vessels and workers operating inside the boundaries of the windfarm off the coast of Scotland. The connectivity also allows workers to be in touch on a regular basis through video calls and emails whilst they are at sea.
The Moray East offshore windfarm project is aimed at generating electricity using renewable energy; it will be able to fulfil approximately 40% of the total electricity demand in Scotland and can power-up to 950,000 homes in the UK.
“Building efficiencies into the construction and operations of a windfarm is a challenge without superfast and reliable connectivity. Vilicom will provide network connectivity to all project operating sea vessels and provides functionality that enables communication not only between workers at sea but also communication back home and for use in leisure time,” states Sean Keating, CEO of Vilicom.
“Mavenir is delighted to partner with Vilicom for this important and equally complex private network system. Private networks are increasingly becoming more prevalent and we look forward to collaborating with Vilicom to develop further such use cases and applications. This project highlights the relevance and importance of advanced communications in a real application scenario,” states Stefano Cantarelli, Chief Marketing Officer of Mavenir.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Vilicom:
Vilicom is at the forefront of designing, installing and managing the global networks that give people in over 20 countries and four continents the freedom to communicate and work from anywhere. Vilicom’s consultancy and system integration services harness wireless technology, data and intelligent analytics across every industry sector to deliver unprecedented productivity and efficiencies. Vilicom works with some of the biggest (and, indeed, the smallest) technology-driven companies in the world, offering insight-led consultancy and advice on everything from vendor selections and technology strategy to mergers, acquisitions and project delivery.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005014/en/
Contact information
Mavenir PR Contacts:
Mavenir
Emmanuela Spiteri
PR@mavenir.com
Global PR (EMEA)
Kevin Taylor
KTaylor@GlobalResultsPR.com
Global PR (US)
Casey Bush
mavenir@GlobalResultsPR.com
Vilicom PR Contacts:
PR Consultant
Leila Hrycyszyn
leila@leilapr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom